Intriguingly, the suppression of DAB2IP could subsequently reverse the T-cell-mediated promotion of RCC cell invasion.117 The interaction in this course concerning immunotherapy treatment with the checkpoint inhibitor nivolumab in RCC patients has been recently described. Here, DAB2IP is linked to renal cell carcinoma.